Dyrenium (Triamterene) Patent Expiration, LOE Window & CMS Spending

Dyrenium (Triamterene) by Advanz (Us): Off-Patent Genericized (AB Competition), 2 AB generics, $262K 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAdvanz (Us)
FDA Application & PathwayN013174 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$262K
2024 Medicare Part D Spend$262K
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 21.2% 2-yr change)